A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
Julie C RefardtCornelia ImberClara Odilia SailerNica JeanlozLaura PotassoAlexander KutzAndrea WidmerSandrine A UrwylerFahim EbrahimiDeborah R VogtBettina WinzelerMirjam Christ-CrainPublished in: Journal of the American Society of Nephrology : JASN (2020)
Among hospitalized patients with SIAD treated with fluid restriction, those who received empagliflozin had a larger increase in plasma sodium levels compared with those who received placebo. This finding indicates that empagliflozin warrants further study as a treatment for the disorder.